Three Seasons Wealth LLC Acquires Shares of 9,315 Arrowhead Pharmaceuticals, Inc. $ARWR

Three Seasons Wealth LLC bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,315 shares of the biotechnology company’s stock, valued at approximately $584,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership raised its position in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after purchasing an additional 2,017,489 shares during the last quarter. Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $113,159,000. Fred Alger Management LLC increased its stake in Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock valued at $121,693,000 after purchasing an additional 1,526,164 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in Arrowhead Pharmaceuticals in the third quarter worth about $34,249,000. Finally, Vestal Point Capital LP purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $59,751,000. 62.61% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. The trade was a 4.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 26,065 shares of company stock worth $1,912,662. Insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

ARWR has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Sanford C. Bernstein increased their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Chardan Capital reissued a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $88.17.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $71.82 on Thursday. The firm’s 50-day moving average price is $77.72 and its 200-day moving average price is $69.44. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.30 and a 52-week high of $87.83. The company has a market cap of $10.12 billion, a PE ratio of -33.40 and a beta of 1.26. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period in the previous year, the company earned $2.75 earnings per share. The firm’s quarterly revenue was down 86.4% on a year-over-year basis. As a group, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.